V8 Peptides — Engineered Performance
Research Library
How PT-141 Activates Melanocortin Receptors
PT-141Mechanism

How PT-141 Activates Melanocortin Receptors

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

How does PT-141 work at the receptor? It is a cyclic heptapeptide agonist of melanocortin receptors, with research attention on MC3R and MC4R. In cell systems, receptor engagement is read out mainly as Gs-coupled cyclic AMP, and MC4R can also couple to the Kir7.1 channel. Potency and subtype selectivity vary with the assay, so they must be measured under the conditions of the study. Supplied for laboratory research use only.

PT-141, the research name for bremelanotide, is one of a small set of cyclic peptides used to probe the melanocortin receptor family. Questions about its mechanism tend to arrive as a single sentence, "what does it bind and what happens next", but the answer has layers: a receptor family with five members, a signalling cascade that can be read out several ways, a ligand that is selective only in a relative sense, and a body of structural work that explains why a seven-residue ring can fit a seven-transmembrane receptor. This article walks through those layers from the point of view of a laboratory that wants to design an assay, not from the point of view of any outcome in a living organism. It is intended as the receptor-pharmacology companion to the PT-141 research overview, which covers handling and general background.

All statements about V8 material come from the PT-141 product page: a 10 mg vial of lyophilized powder, ≥98% purity by HPLC, molecular formula C50H68N14O10, sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, stored refrigerated at 2–8 °C or at −20 °C for the long term, and sold for laboratory research use only.

The melanocortin receptor family in one section

Melanocortin receptors are class A G-protein-coupled receptors. A structure-and-function review describes five subtypes, MC1R to MC5R, each with a distinct tissue expression pattern, all sharing the seven-transmembrane architecture and coupling to G proteins that raise intracellular cyclic AMP (Yang, 2011). Their natural agonists are the melanocortin peptides cut from the precursor pro-opiomelanocortin: α-, β- and γ-melanocyte-stimulating hormone and adrenocorticotropic hormone. The same system has two natural antagonists, agouti and agouti-related protein, which is unusual among peptide hormone families.

Two of the five subtypes dominate the literature on PT-141. MC4R, and to a lesser degree MC3R, are expressed in the central nervous system, and the central melanocortin pathway has been called one of the best-characterized neuronal circuits involved in energy homeostasis (Cone, 2005). That is the reason a melanocortin agonist is described on the product page as a tool for "central melanocortin signaling" and "neuroendocrine models". MC1R, by contrast, is the subtype that drives pigment production in melanocytes, which is why the closely related molecule melanotan II appears in melanogenesis assays. The table below keeps the subtypes straight for assay planning.

SubtypeWhere it is characterizedWhy it matters for an assay
MC1RPigment cells (melanocytes), per the melanotan literatureMelanogenesis and cAMP readouts in pigment-cell models; often a counter-screen for a CNS-focused ligand
MC2RAdrenal cortexThe Yang (2011) review reports that its determinants for ACTH binding and signalling differ from those of the other subtypes; often used as a selectivity control
MC3RCentral nervous systemBinding and functional assays; one of the two subtypes named on the PT-141 product page
MC4RCentral nervous systemPrimary target for central melanocortin signalling work; structurally resolved
MC5RExocrine tissues and othersIncluded in full-panel selectivity profiling

Where PT-141 sits among melanocortin ligands

PT-141 is a cyclic heptapeptide built on the same lactam-bridged scaffold as melanotan II. The ring is formed by an amide bond between the side chains of aspartic acid and lysine, the sequence includes norleucine in place of methionine at the N-terminal position and D-phenylalanine at the position that corresponds to residue 7 of α-MSH, and the molecule differs from melanotan II only at the C-terminus, where PT-141 ends in a free carboxylic acid and melanotan II in an amide. A historical review of melanocortin analogs describes PT-141 as a new analog of melanotan II (Hadley and Dorr, 2006). The comparison with its parent is developed in PT-141 vs melanotan II; the structural reasons behind each modification are in the melanotan II overview.

The practical consequence for pharmacology is that PT-141 carries the same recognition core as α-MSH, the His-D-Phe-Arg-Trp stretch visible in the sequence, held in a conformationally restricted ring. Rigidifying a flexible peptide into a ring generally reduces the entropic cost of binding and protects against peptidases, which is part of why such analogs are used as reference ligands. Whether a given ring size and C-terminus favour one subtype over another is an empirical question answered receptor by receptor, and published selectivity values depend on the cell line, the receptor expression level and the readout. For that reason this article does not quote affinity numbers; a laboratory should generate its own under its own conditions.

What binding looks like at atomic resolution

For a long time melanocortin ligand design relied on pharmacophore models and mutagenesis. That changed with structures of MC4R. A 2020 Science paper reported the structure of human MC4R bound to the antagonist SHU9119 at 2.8 Å and identified calcium as a cofactor complexed with residues of both the receptor and the peptide ligand; extracellular calcium raised the affinity and potency of α-MSH at the receptor by 37-fold and 600-fold respectively (Yu et al., 2020). The same paper showed that the crystallized construct could couple to the ion channel Kir7.1 even though it lacked cAMP stimulation, pointing to a G-protein-independent signalling mode. A 2021 Cell Research paper then reported cryo-electron microscopy structures of MC4R in complex with Gs protein and two peptide agonists, NDP-α-MSH and setmelanotide, at 2.9 and 2.6 Å resolution (Heyder et al., 2021).

Neither paper used PT-141, so none of the detailed contacts they describe can be assigned to it without new work. What they provide is the framework: a peptide agonist sits in an orthosteric pocket built from the transmembrane helices, a metal ion contributes to the interface, and activation propagates to Gs. A laboratory using PT-141 as a reference agonist inherits that framework, and it explains one practical point that is easy to overlook: calcium concentration in the assay buffer is part of the experimental system. A buffer prepared without divalent cations and one prepared with physiological calcium may report different potencies for the same ligand.

Signalling readouts: what a mechanism assay actually measures

When a paper says a peptide "activates" a melanocortin receptor, the claim is operational: a particular readout moved. The canonical readout is cyclic AMP accumulation through Gs, which the receptor-family review describes as the main intracellular route (Yang, 2011). Others in routine use include reporter genes driven by a cAMP-responsive element, receptor internalization imaging, and, since the Kir7.1 finding, electrophysiological measurement of channel activity (Yu et al., 2020). Each readout has its own amplification, its own time scale and its own sensitivity to receptor reserve, so potency can legitimately differ between them for the same compound.

ReadoutWhat it capturesCommon pitfalls
cAMP accumulationGs-coupled activation, end-point or kineticPhosphodiesterase activity shapes the curve; include an inhibitor consistently across plates
CRE-reporter geneIntegrated downstream transcriptionSlow and amplified; partial agonists can look like full agonists
Receptor internalizationLigand-driven traffickingNeeds tagged receptors; imaging thresholds are subjective
Kir7.1 channel activityG-protein-independent coupling reported for MC4RRequires co-expression and electrophysiology expertise
Radioligand or fluorescent competition bindingAffinity, not functionA strong binder can be an antagonist; pair with a functional assay

The difference between binding and function deserves emphasis. Binding assays report that a ligand occupies the receptor; they do not report what the receptor does next. A complete mechanism study therefore pairs a competition-binding experiment with at least one functional readout, and includes reference compounds whose behaviour is known: the endogenous agonist α-MSH, a high-potency synthetic agonist, and an antagonist such as SHU9119, the ligand used in the MC4R crystal structure.

Designing a clean receptor-pharmacology experiment

Because PT-141 is a research reagent and not a validated standard, the burden of experimental rigour falls on the laboratory. The points below are drawn from general receptor-pharmacology practice, not from any single study on this compound.

  • Choose the receptor background deliberately. Parental cells that lack the receptor serve as a negative control; cells expressing a single subtype give clean data; a native cell type gives physiological context but a mixed receptor population.
  • Run a reference panel on every plate. α-MSH and a high-potency analog establish the maximal response, and an antagonist confirms that the signal is receptor-mediated.
  • Fix the buffer. Because calcium modulates the affinity of peptide ligands at MC4R (Yu et al., 2020), record and hold constant the divalent cation content.
  • Generate full concentration-response curves. A single concentration cannot distinguish a partial agonist from a weak full agonist, and curve shape is the evidence for potency and efficacy.
  • Prepare stock from a known mass. Molar concentration is the vial mass divided by the molar mass and the diluent volume; the formula weight from C50H68N14O10 is about 1,025 g/mol. The reconstitution calculator does the arithmetic, and the general method is in peptide reconstitution volume calculations.
  • Record the lot. Batch documentation, where published, belongs in the notebook next to every data set; see the COA page and how to read a COA.

What preclinical melanocortin literature does and does not say about PT-141

Much of what is written about melanocortin agonists in animal models is based on melanotan II or on other analogs, not PT-141. The classic example is a 1997 Nature paper which used cyclic melanocortin analogs, including the agonist MTII, to show that intracerebroventricular administration of the agonist inhibited feeding in four models of hyperphagia, and that co-administration of the antagonist SHU9119 blocked this inhibition (Fan et al., 1997). It is a landmark for the receptor-level argument, but it concerns a different molecule, a different route and a different question. A responsible summary of the PT-141 literature has to keep that separation explicit.

The 2006 review of melanocortin analogs places PT-141 historically as a derivative of melanotan II (Hadley and Dorr, 2006), and that is a statement about lineage and not about its receptor profile. If an experiment depends on subtype selectivity, the lab must measure it. The questions that remain open for any PT-141 study include which subtypes respond in the chosen cell system, how much of the signal is cAMP-dependent versus channel-mediated, and how the compound behaves in the presence of calcium variations. These are design questions, and the answers belong to the data produced, not to an article.

Mechanism claims to avoid

Three habits weaken mechanism write-ups. The first is borrowing a structural contact from the MC4R structures and assigning it to PT-141 without a mutagenesis or docking experiment. The second is describing "selectivity" without naming the panel, the readout and the cell line. The third is handling a cAMP EC50 as if it were a measure of affinity; the two are related by receptor reserve and assay amplification. A clean sentence in a methods section states the cell system, the readout, the reference ligands and the lot of material used.

Related reading for assay planning includes PT-141 purity testing, where to buy PT-141 for research, and what is PT-141. Sourcing and structure-activity questions are developed in other articles in the library, so this one stays with receptor mechanism.

Summary for the bench

PT-141 is a conformationally constrained melanocortin agonist whose recognition core is shared with α-MSH. Its mechanism in a cell system is best described as engagement of one or more of the five melanocortin receptors and, for the subtypes that couple to Gs, a rise in cyclic AMP; at MC4R an additional, G-protein-independent route through Kir7.1 has been described for the receptor itself. Everything beyond that, including potency, selectivity and kinetics, has to be measured under the conditions of the study. This material is supplied for laboratory research use only; the full catalogue is on the shop page.

Frequently asked questions

What receptor does PT-141 act on?

The product page describes it as a melanocortin agonist with research attention on MC3R and MC4R, the subtypes expressed in the central nervous system. Subtype selectivity should be measured in the assay system chosen, because published values depend on the cell line and readout.

How does PT-141 differ structurally from melanotan II?

Both share the lactam-bridged cyclic heptapeptide scaffold. PT-141 ends in a free carboxylic acid and melanotan II in an amide, which is the only difference in the sequences listed on the V8 product pages.

What signalling pathway follows melanocortin receptor activation?

Melanocortin receptors couple to G proteins and signal through cyclic AMP (Yang, 2011). For MC4R, coupling to the ion channel Kir7.1 independent of G proteins has also been reported (Yu et al., 2020).

Does calcium matter in a melanocortin binding assay?

The MC4R structure paper found calcium complexed with both receptor and peptide ligand, and extracellular calcium raised the potency of α-MSH by 600-fold (Yu et al., 2020). Hold buffer cations constant and record them.

Which reference compounds belong in a PT-141 mechanism experiment?

The endogenous agonist α-MSH, a high-potency synthetic agonist, and an antagonist such as SHU9119 allow the lab to calibrate the maximal response and to confirm that the signal is receptor-mediated.

Are there structures of PT-141 bound to a receptor?

The published MC4R structures used SHU9119, NDP-α-MSH and setmelanotide. None of them used PT-141, so contacts reported there should not be assigned to PT-141 without new evidence.

Is a cAMP EC50 the same as binding affinity?

No. A functional EC50 depends on receptor reserve, amplification and incubation time, while affinity comes from competition or saturation binding. A thorough study reports both.

How do I calculate the molar concentration of a PT-141 stock?

Divide the vial mass by the molar mass (about 1,025 g/mol from the formula) to get moles, then divide by the diluent volume. The calculator on the site does this and keeps the units straight.

Where do I find batch documentation for PT-141?

The product page lists the documentation items provided with each lot, and published certificates appear on the COA page where available. Always record the lot number with your data.

Is PT-141 sold as a consumer product?

No. V8 supplies it strictly for laboratory research use only; it is not a drug, food or cosmetic and is not intended for human or animal consumption.

Related reading: Buying PT-141 for Research: What to Evaluate, PT-141 Structure-Activity: Nle, D-Phe and the Ring, PT-141 vs MT-2: Formula, Mass and Analytical Differences.

References

  1. Cone RD. Anatomy and regulation of the central melanocortin system. Nat Neurosci. 2005;8(5):571-578. doi:10.1038/nn1455
  2. Yang Y. Structure, function and regulation of the melanocortin receptors. Eur J Pharmacol. 2011;660(1):125-130. doi:10.1016/j.ejphar.2010.12.020
  3. Yu J, Gimenez LE, Hernandez CC, et al. Determination of the melanocortin-4 receptor structure identifies Ca2+ as a cofactor for ligand binding. Science. 2020;368(6489):428-433. doi:10.1126/science.aaz8995
  4. Heyder NA, Kleinau G, Speck D, et al. Structures of active melanocortin-4 receptor–Gs-protein complexes with NDP-α-MSH and setmelanotide. Cell Res. 2021;31(11):1176-1189. doi:10.1038/s41422-021-00569-8
  5. Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-930. doi:10.1016/j.peptides.2005.01.029
  6. Fan W, Boston BA, Kesterson RA, Hruby VJ, Cone RD. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature. 1997;385(6612):165-168. doi:10.1038/385165a0

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.